Indivior (Nasdaq: INDV) priced an upsized $450.0 million offering of 0.625% convertible senior notes due 2031, with a 30-day option to purchase an additional $50.0 million.
Net proceeds are estimated at approximately $437.7 million (or ~$486.4 million if option exercised). The initial conversion price is about $41.66 per share, a ~35.0% premium to the March 12, 2026 closing price.
Loading...
Loading translation...
Positive
Net proceeds of ~$437.7M (or ~$486.4M if option exercised)
$239M of proceeds allocated to repay term loan borrowings
Initial conversion price of $41.66 could lead to future dilution if converted
Concurrent repurchases may have increased the initial conversion price
Notes add senior unsecured debt until repaid or converted, extending leverage through 2031
Key Figures
Convertible notes size:$450,000,000Prior offering size:$400,000,000Overallotment option:$50,000,000+5 more
8 metrics
Convertible notes size$450,000,000Aggregate principal amount of 0.625% convertible senior notes due 2031
Prior offering size$400,000,000Previously announced aggregate principal amount before upsizing
Overallotment option$50,000,000Additional principal amount available to initial purchasers for 30 days
Coupon rate0.625% per annumInterest on convertible senior notes, payable semi-annually
Initial conversion rate24.0033 shares per $1,000Initial conversion rate of notes into common stock
Initial conversion price$41.66 per shareImplied from initial conversion rate
Conversion premium35.0%Premium over last reported INDV share price on March 12, 2026
Estimated net proceeds$437.7 millionNet proceeds excluding full exercise of option; $486.4M if fully exercised
Market Reality Check
Price:$30.86Vol:Volume 6,979,270 is 2.77x...
high vol
$30.86Last Close
VolumeVolume 6,979,270 is 2.77x the 20-day average of 2,523,177, signaling elevated trading interest ahead of the convertible pricing.high
TechnicalShares traded above the 200-day MA, with price at $30.86 versus the $26.21 200-day moving average, despite a 6% decline.
Peers on Argus
INDV fell 6%, while key peers like BHC (-5.61%), AMRX (-2.3%), SUPN (-2.59%), HC...
1 Down
INDV fell 6%, while key peers like BHC (-5.61%), AMRX (-2.3%), SUPN (-2.59%), HCM (-1.8%) and KNSA (-0.28%) also declined but less, pointing to a more company-specific reaction to the convertible notes deal.
Completion of U.K.-to-U.S. redomiciliation and continued Nasdaq listing under INDV.
Pattern Detected
Recent fundamentally positive updates often saw modest or even negative next-day moves, with only one clear divergence on favorable clinical/health-economic news.
Recent Company History
Over recent months, Indivior reported strong 2025 financial results, with SUBLOCADE driving growth and a new $400M share repurchase authorization, and completed redomiciliation to a U.S. parent on Jan 26, 2026. It also announced upcoming earnings and investor conference participation, plus a real-world study showing cost benefits for SUBLOCADE-adherent patients. Against this backdrop of operational and financial progress, the new $450M convertible notes financing shifts focus to capital structure and balance sheet optimization.
Market Pulse Summary
This announcement detailed a $450M 0.625% convertible notes financing, upsized from $400M, with an a...
Analysis
This announcement detailed a $450M 0.625% convertible notes financing, upsized from $400M, with an additional $50M option and a 35% conversion premium. Indivior plans to use about $239M plus $102M of cash to retire its term loan and revolver, allocate roughly $75M to concurrent share repurchases, and apply the balance to general corporate purposes. Investors may watch how this affects leverage, future dilution, and execution on the company’s growth plans.
Key Terms
convertible senior notes, rule 144a, qualified institutional buyers, fundamental change, +1 more
5 terms
convertible senior notesfinancial
"announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031"
Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.
rule 144aregulatory
"in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act"
Rule 144A is a regulation that makes it easier for companies to sell private bonds to large investors without going through all the usual rules that apply to public sales. It matters because it helps companies raise money more quickly and privately, often attracting big investors looking for special deals.
qualified institutional buyersfinancial
"in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A"
Qualified institutional buyers are large organizations, like big investment firms or banks, that are allowed to buy certain types of investment opportunities not available to everyday investors. Their size and experience matter because it ensures they understand and can handle complex financial deals, making markets more efficient and secure.
fundamental changefinancial
"If certain events that constitute a “fundamental change” occur, then, subject to a limited exception, noteholders may require Indivior to repurchase"
A fundamental change is a major shift in how a company or economy operates, like a new technology or a big change in leadership. It matters because such changes can affect the value or stability of investments, making them more or less attractive. Think of it like a major upgrade or shift in the rules of a game that can change the outcome.
registration requirementsregulatory
"cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act"
Registration requirements are the legal steps a company or security must complete with regulators before offering shares, bonds, or certain products to the public. They matter to investors because these rules force companies to disclose key facts—like financials, risks, and who’s in charge—so buyers can make informed choices, much like checking a permit and inspection report before buying a house to reduce surprise problems.
AI-generated analysis. Not financial advice.
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on March 17, 2026, subject to customary closing conditions.
The notes will be senior, unsecured obligations of Indivior and will accrue interest at a rate of 0.625% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2026. The notes will mature on March 15, 2031, unless earlier repurchased, redeemed or converted. Before December 16, 2030, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after December 16, 2030, noteholders will have the right to convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Indivior will settle conversions by paying or delivering cash and, if applicable, shares of its common stock.. The initial conversion rate is 24.0033 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $41.66 per share of common stock. The initial conversion price represents a premium of approximately 35.0% over the last reported sale price of the common stock on The Nasdaq Global Select Market on March 12, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.
The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Indivior’s option at any time, and from time to time, on or after March 20, 2029 and on or before the 25th scheduled trading day before the maturity date, but only if the last reported sale price per share of Indivior’s common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If certain events that constitute a “fundamental change” occur, then, subject to a limited exception, noteholders may require Indivior to repurchase their notes at a cash repurchase price equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.
Indivior estimates that the net proceeds to it from the offering will be approximately $437.7 million (or approximately $486.4 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and Indivior’s estimated offering expenses. Indivior intends (1) to use approximately $239 million of the net proceeds from the offering together with approximately $102 million of cash on hand to repay borrowings under and terminate the note purchase agreement that governs its term loan and revolving credit facility, (2) to use approximately $75.0 million of the net proceeds from the offering to repurchase approximately 2.4 million shares of its common stock from certain purchasers of the notes concurrently with the pricing of the offering in privately negotiated transactions effected through one of the initial purchasers or an affiliate thereof, at a price per share equal to the last reported sale price per share of the common stock on The Nasdaq Global Select Market on March 12, 2026 and (3) the remainder of the net proceeds from the offering for general corporate purposes.
The concurrent repurchases of approximately $75.0 million of common stock described above may have resulted in the common stock trading at prices that were higher than would be the case in the absence of these repurchases, which may have resulted in a higher initial conversion price for the notes.
The notes were only offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope.
Important Cautionary Note Regarding Forward-looking Statements
Certain statements contained herein are forward-looking statements. Forward-looking statements include, among other things, express and implied statements pertaining to: (i) whether Indivior will issue the notes; (ii) the timing of the closing of the offering; (iii) the expected amount and intended use of the net proceeds from the offering; (iv) Indivior’s expectations regarding the effects of the concurrent common stock repurchases; and (v) statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. For information about some additional risks and important factors that could affect our future results and financial condition, see the discussion of “Risk Factors” in our Annual Report on Form 10-K filed February 26, 2026 and our other filings with the SEC.
We have based the forward-looking statements in this release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this release speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement.
For Further Information
Investors: Jason Thompson Indivior Pharmaceuticals Tel: 804-402-7123 E-mail: jason.thompson@indivior.com
What did Indivior (INDV) announce about the March 2026 convertible note offering?
Indivior announced a priced, upsized $450.0 million offering of 0.625% convertible senior notes due 2031. According to the company, the offering includes a 30-day option for an extra $50.0 million and is expected to settle March 17, 2026.
How much net proceeds will Indivior (INDV) receive from the convertible notes offering?
Indivior expects approximately $437.7 million in net proceeds, or about $486.4 million if the option is exercised. According to the company, proceeds will fund debt repayment, a $75.0 million share repurchase, and general corporate purposes.
What are the conversion terms and price for INDV 0.625% notes due 2031?
The initial conversion rate is 24.0033 shares per $1,000 principal, equating to an initial conversion price of about $41.66 per share. According to the company, this represents roughly a 35.0% premium to the March 12, 2026 closing price.
How will Indivior (INDV) use proceeds from the convertible notes offering?
Indivior will use ~ $239 million of proceeds plus ~$102 million cash on hand to repay its term loan, $75.0 million to repurchase common stock, and the remainder for general corporate purposes, according to the company.
When can INDV noteholders convert the 0.625% convertible notes into shares?
Noteholders may convert upon certain events before December 16, 2030 and at any time from December 16, 2030 until two scheduled trading days before maturity. According to the company, conversions may be settled in cash, stock, or both.
Are there redemption or repurchase rights for INDV convertible notes due 2031?
Indivior may redeem the notes for cash on or after March 20, 2029 if share price conditions are met; noteholders may require repurchase after a fundamental change. According to the company, customary limitations and conditions apply.
